CN Patent

CN112469417A — 恶拉戈利钠组合物和方法

Assigned to AbbVie Inc · Expires 2021-03-09 · 5y expired

What this patent protects

本发明涉及恶拉戈利钠(elagolix sodium)的组合物，以及其制备方法和中间物。

USPTO Abstract

本发明涉及恶拉戈利钠(elagolix sodium)的组合物，以及其制备方法和中间物。

Drugs covered by this patent

Patent Metadata

Patent number: CN112469417A
Jurisdiction: CN
Classification: —
Expires: 2021-03-09
Drug substance claim: No
Drug product claim: No
Assignee: AbbVie Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.